High school exit exams are affecting a growing majority of high school students. Although exit testing polices were enacted with the goal of improving student achievement as well as postsecondary outcomes, they also have the potential for negative effects. To better understand the effects of exit testing policies, in this article the authors systematically review 46 unique studies that pertain to four domains of expected influence: student achievement, graduation, postsecondary outcomes, and school response. The evidence reviewed indicates that exit tests have produced few of the expected benefits and have been associated with costs for the most disadvantaged students. This review suggests policy modifications that may attenuate some of the negative effects.
FDA's approval of cemiplimab-rwlc on February 22, 2021, follows prior approvals of pembrolizumab and atezolizumab for similar indications as first-line treatment for patients with programmed death ligand-1 (PD-L1)–high advanced non–small cell lung cancer (NSCLC). Approvals of these anti–PD-L1 agents were supported by statistically significant and clinically meaningful improvements in overall survival (OS) in international, multicenter, active-controlled randomized trials. In KEYNOTE-024, the OS HR was 0.60 [95% confidence interval (CI), 0.41–0.89; P = 0.005] favoring pembrolizumab over platinum-doublet chemotherapy. In IMpower110, the OS HR was 0.59 (95% CI, 0.40–0.89; P = 0.0106) favoring atezolizumab over platinum-doublet chemotherapy. In Study 1624, the OS HR was 0.68 (95% CI, 0.53–0.87; P = 0.0022) favoring cemiplimab-rwlc over platinum-doublet chemotherapy. The progression-free survival (PFS) effect sizes for these anti–PD-L1 antibodies were also comparable across their respective registrational trials, and their safety profiles were consistent with the anti–PD-L1 class adverse event profile. The consistent survival benefits and manageable toxicity profiles of these single-agent anti–PD-L1 antibodies have established them as important treatment options in the PD-L1–high NSCLC treatment landscape. FDA approvals of these anti–PD-L1 antibodies, based on their favorable benefit-risk profiles, present effective chemotherapy-free therapeutic options for patients with advanced PD-L1–high NSCLC in the United States.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.